Bionano Genomics, Inc. (BNGO)

Market Cap	18.72M
Revenue (ttm)	27.43M
Net Income (ttm)	-74.33M
Shares Out	4.68M
EPS (ttm)	-32.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	316,881
Open	4.050
Previous Close	4.130
Day's Range	3.800 - 4.080
52-Week Range	2.680 - 33.720
Beta	2.06
Analysts	Buy
Price Target	7.67 (+91.75%)
Earnings Date	Aug 14, 2025

About BNGO

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome anal...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 21, 2018
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: BNGO
• Website: https://bionano.com

Financial Performance

In 2024, Bionano Genomics's revenue was $30.78 million, a decrease of -14.79% compared to the previous year's $36.12 million. Losses were -$112.02 million, -51.82% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price target is $7.67, which is an increase of 91.75% from the latest price.

Price Target

$7.67

(91.75% upside)

Analyst Consensus: Buy